Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II).

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Infectious Diseases

• Publication date

  2005-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1086/429929PMID 15871127
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• African trypanosomiasis or sleeping sickness--fact-sheet.

  2004cited by this paper
• Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness.

  2004influential reference
• Eflornithine for the treatment of human African trypanosomiasis

  2003cited by this paper
• Trypanosoma brucei gambiense African trypanosomiasis: differences between men and women in severity of disease and response to treatment.

  2002cited by this paper
• The phenomenon of treatment failures in Human African Trypanosomiasis

  2001cited by this paper
• The situation of sleeping sickness in Angola: a calamity

  2001influential reference
• Clinical description of encephalopathic syndromes and risk factors for their occurrence and outcome during melarsoprol treatment of human African trypanosomiasis

  2001cited by this paper
• Infectious Diseases of the Nervous System

  2000cited by this paper
• [African human trypanosomiasis. Therapeutic strategies].

  2000cited by this paper
• Treatment of human African trypanosomiasis.

  2000cited by this paper
• Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial.

  2000influential reference
• Neurological aspects of human African trypanosomiasis

  2000cited by this paper
• [Therapeutic failure of melarsoprol among patients treated for late stage T.b. gambiense human African trypanosomiasis in Uganda].

  1999cited by this paper
• Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda.

  1999cited by this paper
• Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee.

  1998cited by this paper
• Alternative application of melarsoprol for treatment of T. B. gambiense sleeping sickness. Preliminary results.

  1995cited by this paper
• Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness.

  1995cited by this paper
• Pharmacokinetics of melarsoprol in uninfected vervet monkeys.

  1994cited by this paper
• [2 epidemics of arsenical encephalopathy in the treatment of trypanosomiasis, Uganda, 1992-1993].

  1994cited by this paper
• The treatment of human African trypanosomiasis.

  1994cited by this paper
• Gambiense trypanosomiasis: frequency of, and risk factors for, failure of melarsoprol therapy.

  1994cited by this paper
• Pharmacokinetic properties of the trypanocidal drug melarsoprol.

  1993cited by this paper
• Current situation of African trypanosomiasis.

  1993cited by this paper
• Human trypanosomiasis in the Ivory Coast: therapy and problems.

  1993cited by this paper
• An in vitro bioassay for quantification of melarsoprol in serum and cerebrospinal fluid.

  1992cited by this paper
• In vitro drug sensitivity of Trypanosoma gambiense isolates.

  1989influential reference
• Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness.

  1989cited by this paper
• Neuropathies arsenicales après traitement de la trypanosomiase humaine au melarsopol. Observations cliniques à propos de 5 cas

  1988cited by this paper
• Medical Adventure. Some Experiences of a General Practitioner

  1929cited by this paper

• Interventions for Neglected Diseases Caused by Kinetoplastid Parasites: A One Health Approach to Drug Discovery, Development, and Deployment

  2025cites this paper
• To Explore Potential Inhibitors Against Various Enzymatic Targets of Human African Trypanosomiasis.

  2024cites this paper
• A man in his sixties with life-threatening febrile illness after travel abroad.

  2024cites this paper
• Further Investigations of Nitroheterocyclic Compounds as Potential Antikinetoplastid Drug Candidates

  2023cites this paper
• The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration

  2023cites this paper
• An Update on African Trypanocide Pharmaceutics and Resistance

  2022cites this paper
• Safety and efficacy of oral fexinidazole in children with gambiense human African trypanosomiasis: a multicentre, single-arm, open-label, phase 2–3 trial

  2022cites this paper
• Clinical trials as disease control? The political economy of sleeping sickness in the Democratic Republic of the Congo (1996-2016).

  2022cites this paper
• Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study

  2021cites this paper
• Temperate Zone Plant Natural Products—A Novel Resource for Activity against Tropical Parasitic Diseases

  2021cites this paper
• Long-term sequelae of congenital gambiense human African trypanosomiasis.

  2021cites this paper
• Prevention, Control and Treatment Strategies for Trypanosomiasis: A Review

  2020cites this paper
• Sleeping Sickness at the Crossroads

  2020cites this paper
• The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History.

  2020cites this paper
• Screening Marine Natural Products for New Drug Leads against Trypanosomatids and Malaria

  2020cites this paper
• Prescription of concomitant medications in patients treated with Nifurtimox Eflornithine Combination Therapy (NECT) for T.b. gambiense second stage sleeping sickness in the Democratic Republic of the Congo

  2020cites this paper
• Clinical Study on the Melarsoprol-Related Encephalopathic Syndrome: Risk Factors and HLA Association

  2020cites this paper
• The Drugs of Sleeping Sickness: Their Mechanisms of Action and Resistance, and a Brief History

  2020cites this paper
• Clinical and Neuropathogenetic Aspects of Human African Trypanosomiasis

  2019cites this paper
• Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo

  2018cites this paper
• Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial.

  2018cites this paper
• Novel 1,2-dihydroquinazolin-2-ones: Design, synthesis, and biological evaluation against Trypanosoma brucei.

  2017cites this paper
• Investigating the Functional Roles of LC8, CITFA, and RPB7 in the Multifunctional RNA Polymerase System of Trypanosoma brucei

  2017cites this paper
• The challenging problem of disease staging in human African trypanosomiasis (sleeping sickness): a new approach to a circular question.

  2017cites this paper
• Targeting Trypanosoma brucei FPPs by fragment- based drug discovery

  2017cites this paper
• Human African trypanosomiasis: What are the prospects for control?

  2017cites this paper
• Human African trypanosomiasis.

  2017cites this paper
• Potential Drug Targets in the Pentose Phosphate Pathway of Trypanosomatids.

  2017cites this paper
• Repurposing of the Open Access Malaria Box for Kinetoplastid Diseases Identifies Novel Active Scaffolds against Trypanosomatids

  2015cites this paper
• 6-Arylpyrazine-2-carboxamides: A New Core for Trypanosoma brucei Inhibitors.

  2015cites this paper
• The Selection and Use of Essential Medicines.

  2015cites this paper
• Caractérisation de nouvelles protéines, partenaires potentiels de BILBO1, chez le parasite Trypanosoma brucei

  2014cites this paper
• Treatment options for second-stage gambiense human African trypanosomiasis

  2014cites this paper
• Synthesis, Characterization, Crystal Structure and Antimicrobial Evaluation of a Novel –M–X–M–X– Type Infinite Chain 1D Cu(II) Complex with Eflornithine Hydrochloride Hydrate as Ligand

  2014cites this paper
• Incorporating Scale Dependence in Disease Burden Estimates: The Case of Human African Trypanosomiasis in Uganda

  2014influential citation
• Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis

  2014cites this paper
• 45 – Human African Trypanosomiasis

  2014cites this paper
• A current analysis of chemotherapy strategies for the treatment of human African trypanosomiasis

  2013cites this paper
• Pharmacokinetics and pharmacodynamics utilizing unbound target tissue exposure as part of a disposition-based rationale for lead optimization of benzoxaboroles in the treatment of Stage 2 Human African Trypanosomiasis

  2013cites this paper
• Clinical features, diagnosis, and treatment of human African trypanosomiasis (sleeping sickness).

  2013cites this paper
• Chemotherapy for second-stage human African trypanosomiasis.

  2013cites this paper
• Biogenic trypanocidal sesquiterpenes: lead compounds to design future trypanocidal drugs - a mini review

  2013cites this paper
• Infections of the developing world.

  2013cites this paper
• What Could Be a Primary Cause of Multiple Sclerosis: Is It an Autoimmunity Triggered by Chronic Protozoan Infection?

  2013cites this paper
• Human African trypanosomiasis.

  2013cites this paper
• [Human African trypanosomiasis in Côte d'Ivoire and Burkina Faso: optimization of epidemiologic surveillance strategies].

  2012cites this paper
• Neglected tropical diseases: survey and geometry of randomised evidence

  2012cites this paper
• In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness

  2012influential citation
• Safety and Efficacy of the 10-Day Melarsoprol Schedule for the Treatment of Second Stage Rhodesiense Sleeping Sickness

  2012cites this paper
• La Trypanosomose Humaine Africaine dans l’espace ivoiro-burkinabé : optimisation des stratégies de surveillance épidémiologique

  2012cites this paper
• Trypanocidal Monoterpenes: Lead Compounds to Design Future Trypanocidal Drugs

  2012cites this paper
• The detection and treatment of human African trypanosomiasis.

  2012cites this paper
• An alternative form of melarsoprol in sleeping sickness.

  2012cites this paper
• Human African trypanosomiasis in endemic populations and travellers

  2011cites this paper
• Therapy of vector-borne protozoan infections in nonendemic settings

  2011cites this paper
• Melarsoprol cyclodextrin inclusion complexes for the treatment for human African trypanosomiasis

  2011cites this paper
• State of the art in African trypanosome drug discovery.

  2011influential citation
• New approaches to fluorescence-based diagnostics for human African trypanosomiasis

  2011cites this paper
• From sentinel surveillance for sleeping sickness treatment failure to the development of a pharmacovigilance approach

  2011cites this paper
• Leishmania and Trypanosoma

  2011cites this paper
• From Sentinel Surveillance for Sleeping Sickness Treatment Failure to the Development of a Pharmacovigilance Approach

  2011cites this paper
• Clinical Presentation of T.b. rhodesiense Sleeping Sickness in Second Stage Patients from Tanzania and Uganda

  2011cites this paper
• Isolation of Trypanosoma brucei gambiense from Cured and Relapsed Sleeping Sickness Patients and Adaptation to Laboratory Mice

  2011cites this paper
• Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.

  2010cites this paper
• Chemotherapy for second-stage Human African trypanosomiasis.

  2010cites this paper
• Cardiac Involvement with Parasitic Infections

  2010cites this paper
• NECT Is Next: Implementing the New Drug Combination Therapy for Trypanosoma brucei gambiense Sleeping Sickness

  2010cites this paper
• Immunobiology of African Trypanosomes: Need of Alternative Interventions

  2010cites this paper
• Human African trypanosomiasis

  2010cites this paper
• Potential new drugs for human African trypanosomiasis: some progress at last

  2010cites this paper
• Chemotherapy against human African trypanosomiasis: Is there a road to success?

  2010cites this paper
• Sleeping Sickness: Cause and Control

  2009cites this paper
• The selection and use of essential medicines.

  2009cites this paper
• The synthesis of [delta]-amides of eflornithine to improve oral bioavailability

  2009cites this paper
• Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial.

  2009cites this paper
• Improved melarsoprol therapy for Trypanosoma brucei rhodesiense sleeping sickness

  2009cites this paper
• Improved melarsoprol therapy for "Trypanosoma brucei rhodesiense" sleeping sickness

  2009cites this paper
• Thèse en co-tutelle Pour obtenir le grade de DOCTEUR DE L'UNIVERSITE DE LIMOGES Discipline : Biologie-Science-Santé Spécialité : Parasitologie

  2008cites this paper
• Apports diagnostiques au cours de la trypanosomose humaine africaine

  2008cites this paper
• Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study

  2008cites this paper
• Présentation clinique et pronostic de la maladie du sommeil chez des enfants d'âge préscolaire au Sud-Soudan

  2008influential citation
• sickness in Sudan : cohort study sleepingTrypanosoma brucei gambiensefor Safety and effectiveness of first line eflornithine

  2008cites this paper
• The selection and use of essential medicines.

  2008cites this paper
• Factors influencing the spread and selection of drug resistance in Human African Trypanosomiasis

  2008influential citation
• Eflornithine is a cost‐effective alternative to melarsoprol for the treatment of second‐stage human West African trypanosomiasis in Caxito, Angola

  2008cites this paper
• Clinical presentation and treatment outcome of sleeping sickness in Sudanese pre-school children.

  2007cites this paper
• Recommendations of the informal consultation on issues for clinical product development for human African trypanosomiasis; Geneva, Switzerland, 9-10 September 2004

  2007cites this paper
• 28 Antiprotozoal drugs

  2007cites this paper
• Drugs and drug resistance in African trypanosomiasis.

  2007cites this paper
• Cardiac manifestations of parasitic infections part 2: Parasitic myocardial disease

  2007cites this paper
• Treatment failure in hemo-lymphatic stage sleeping sickness patients is related to 1 intrathecal IgM synthesis , cerebrospinal fluid IgM and interleukin-10 2 3 Running title : Markers of CNS involvement in HAT 4 5 L

  2007cites this paper
• Approaches to serious methicillin-resistant Staphylococcus aureus infections with decreased susceptibility to vancomycin: clinical significance and options for management

  2007cites this paper
• Treatment Failure Related to Intrathecal Immunoglobulin M (IgM) Synthesis, Cerebrospinal Fluid IgM, and Interleukin-10 in Patients with Hemolymphatic-Stage Sleeping Sickness

  2007cites this paper
• Human African trypanosomiasis: pharmacological re‐engagement with a neglected disease

  2007cites this paper
• Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series

  2007cites this paper
• Combination therapy for sleeping sickness: a wake-up call.

  2007cites this paper
• Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness.

  2007cites this paper
• A simple and valid tool distinguished efficacy from effectiveness studies.

  2006cites this paper
• Human African trypanosomiasis–neurological aspects

  2006cites this paper
• Isolation, propagation and characterization of "Trypanosoma brucei gambiense" from human African trypanosomosis patients in south Sudan

  2006influential citation